Leukaemia that was observed in a small number of mitoxantrone treated multiple sclerosis patients may be the result of patients’ genetic make up, Italian researchers said. Variations in genes involved with DNA repair processes and in the gene encoding the CYP3A4 drug-metabolising enzyme were significantly associated with secondary acute promyelocytic leukaemia in a case-control study, according to Francesco Lo-Coco et al, Italy.
Read more.
Tags: Neurology
